IONIS PHARMACEUTICALS INC
For the period ended Dec 31, 2024. Filed Feb 19, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 19, 2025
IONS$31.00-21.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except share and par value data)
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $242,077 | $399,266 |
| Short-term investments | 2,055,579 | 1,931,935 |
| Contracts receivable | 92,188 | 97,778 |
| Inventories | 12,512 | 7,441 |
| Other current assets | 217,934 | 205,433 |
| Total current assets | 2,620,290 | 2,641,853 |
| Property, plant and equipment, net | 94,251 | 71,043 |
| Right-of-use assets | 161,856 | 171,896 |
| Deposits and other assets | 127,278 | 105,280 |
| Total assets | $3,003,675 | $2,990,072 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $42,964 | $26,027 |
| Accrued compensation | 69,614 | 67,727 |
| Accrued liabilities | 108,438 | 147,894 |
| Income taxes payable | 34 | 2,151 |
| 0.125 percent convertible senior notes, net | — | 44,332 |
| Current portion of deferred contract revenue | 78,989 | 151,128 |
| Other current liabilities | 9,279 | 8,831 |
| Total current liabilities | 309,318 | 448,090 |
| Long-term deferred contract revenue | 156,504 | 241,184 |
| 1.75 percent convertible senior notes, net | 565,026 | 562,285 |
| 0 percent convertible senior notes, net | 628,535 | 625,380 |
| Liability related to sale of future royalties, net | 542,212 | 513,736 |
| Long-term lease liabilities | 161,805 | 170,875 |
| Long-term obligations | 51,924 | 41,836 |
| Total liabilities | 2,415,324 | 2,603,386 |
| Stockholders’ equity: | ||
| Common stock, $0.001 par value; 300,000,000 shares authorized, 157,908,815 and 144,340,526 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively | 158 | 144 |
| Additional paid-in capital | 2,868,812 | 2,215,098 |
| Accumulated other comprehensive loss | (30,811) | (32,645) |
| Accumulated deficit | (2,249,808) | (1,795,911) |
| Total stockholders’ equity | 588,351 | 386,686 |
| Total liabilities and stockholders’ equity | $3,003,675 | $2,990,072 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.